| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,671 |
1,326 |
$72K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,210 |
985 |
$37K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
281 |
244 |
$13K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
115 |
81 |
$10K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
629 |
371 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
64 |
53 |
$3K |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$761.13 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
55 |
41 |
$29.22 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
53 |
41 |
$16.93 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
351 |
278 |
$0.00 |
| 99442 |
|
31 |
30 |
$0.00 |
| 99401 |
|
21 |
15 |
$0.00 |
| J1094 |
Injection, dexamethasone acetate, 1 mg |
29 |
18 |
$0.00 |
| 3074F |
|
20 |
14 |
$0.00 |
| 96127 |
|
15 |
13 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
14 |
12 |
$0.00 |